Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2007-05-29
2007-05-29
Zeman, Robert A. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S247100, C424S093200, C424S164100, C530S340000
Reexamination Certificate
active
11345736
ABSTRACT:
The present invention provides for methods of treating cardiovascular diseases in a mammal. The methods include a step of administering an effective amount of abotulinumtoxin directly to a blood vessel of a mammal thereby treating a cardiovascular disease.
REFERENCES:
patent: 5092841 (1992-03-01), Spears
patent: 5385935 (1995-01-01), Tamai et al.
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5562907 (1996-10-01), Arnon
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5851786 (1998-12-01), Johnson et al.
patent: 5865794 (1999-02-01), Castro
patent: 5939070 (1999-08-01), Johnson et al.
patent: 5989280 (1999-11-01), Euteneuer et al.
patent: 6057367 (2000-05-01), Stamler et al.
patent: 6063768 (2000-05-01), First
patent: 6102904 (2000-08-01), Vigil et al.
patent: 6121296 (2000-09-01), Schramm et al.
patent: 6183506 (2001-02-01), Penn et al.
patent: 6190404 (2001-02-01), Palmaz et al.
patent: 6196230 (2001-03-01), Hall et al.
patent: 6217608 (2001-04-01), Penn et al.
patent: 6238872 (2001-05-01), Mosseri
patent: 6239118 (2001-05-01), Schatz et al.
patent: 6241758 (2001-06-01), Cox
patent: 6261318 (2001-07-01), Lee et al.
patent: 6264671 (2001-07-01), Stack et al.
patent: 6270521 (2001-08-01), Fischell et al.
patent: 6290961 (2001-09-01), Aoki et al.
patent: 6293959 (2001-09-01), Miller et al.
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306162 (2001-10-01), Patel
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6319505 (2001-11-01), Aoki et al.
patent: 6344055 (2002-02-01), Shukov
patent: 6383509 (2002-05-01), Donovan et al.
patent: 6429189 (2002-08-01), Borodic
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6579847 (2003-06-01), Unger
patent: 6767544 (2004-07-01), Brooks et al.
patent: 6977080 (2005-12-01), Donovan
patent: 7048927 (2006-05-01), Brooks et al.
patent: 2002/0099356 (2002-07-01), Unger et al.
patent: 2003/0185860 (2003-10-01), Brooks
patent: 2003/0211975 (2003-11-01), Unger
patent: 2004/0223975 (2004-11-01), Brooks et al.
patent: WO 11/04922 (2000-02-01), None
patent: WO 01/10458 (2001-02-01), None
patent: WO 01/21213 (2001-03-01), None
patent: WO 01/82947 (2001-11-01), None
patent: WO 02/053181 (2002-07-01), None
Most recent claim set for co-pending U.S. Appl. 10/870,603 (3 pages total).
http://www.wrongdiagnosis.com/h/heart—disease/intro.htm, p. 2 of 5, Jul. 20, 2006.
http://www.medterms.com/script/main/art.asp!articlekey=18312; definition of cardiovascular disease.
Mukherjee et al, Expandable Metal Stents in Achalasia- Is There a Role!, Nov. 9, 2000, Elsevier Science Inc., vol. 95, 2185-2187.
Rappuoli et al., Guidebook to Protein Toxins and Their Use in Cell Biology, 1997, Oxford University Press, pp. 66 and 108.
Muniyappa, R. et al., Am. J. Physiol. Heart Cir. Physiol., vol. 278, (6) pp. H1762-H1768, Jun. 2000.
Johnson, Eric. Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu Rev Microbiol 53: 551-575, 1999.
Schmitt et al. Bacterial toxins: friends for foes! Emerg Infect Dis 5(2): 224-234, 1999.
DePalma, GD et al, Endoscopy, Dec. 2001, vol. 33 (12), pp. 1027-1030.
Tan, EK et al, Movement disorders, vol. 14(2), pp. 345-349, 1999.
Tsuboi et al. Botulinum neurotoxin A blocks cholinergic ganglionic neurotransmission in the dog heart. Jpn J Pharmacol 89(3): 249-254, 2002.
Tsuboi et al. Inotropic, chronotropic, and dromotropic effects mediated via parasympathetic ganglia in the dog heart. Am J Physiol Heart Circ Physiol 279:H1201-H1207, 2000.
Mangrum et al. The evaluation and management of bradycardia. N Eng J Med 342(10): 703-709, 2000.
Aktories, K., et al.,Clostridium botulinum C3 ADP- Ribosyltransferase, Current Topics in Microbiology and Immunology, vol. 175, 1992, 115-131.
Fanci, A.S., et al., 14thEdition Harrison's Principles of Internal Medicine, McGraw- Hill pp. 904-907, 1998.
Fiorentini, C. et al., Bacterial toxins and the Rho GTP- binding protein: what microbes teach us about cell regulation, Cell Death and Differentiation (1998) 5, pp. 720-728.
Nishiki, T., et al. Morphological effects of clostridium botulinum C3 exoenzyme on cultured cells, Jpn. J. Med. Sci. Biol. 43, 1990, 261-262.
Claus, D., et al., Botlinum Toxin: influence on respiratory heart rate variation, Mov Disord Sep. 1995 10(5): 574-579
Girlanda, P., et al., Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system, J. Neurol Neurosurg Psychiatry 1992:55(9):844-5.
Lamanna, C., et al., Cardiac Effects of Botulinal Toxin, Arch Int Pharmacodyn Ther 1988; 293: 69-83.
Malnick, S., et al., Fatal heart block following treatment with botulinum toxin for achalasia, Am J Gastroenterol 2000; 95 (11): 3333-3334.
Nebe, A., et al., No effects on heart-rate variability and cardiovascular reflex tests after boulinum toxin treatment of cervical dystonia, Mov Disord May 1996; 11(3): 337-339.
Sathyamoorthy, V., et al., Separation, purification, particial characterization and comparison of the heavy and light chains of botulinum neurotoxin types A, B and E, The J. of Biol. Chem, vol. 260, No. 19, Sep. 5, pp. 10461-10466, 1985.
Shone, C., et al., A 50-kDa fragment from the NH2-terminus of the heavy subunit of clostridium botulinum type A neurotoxin forms channels in lipid vesicles, Eur. J, Biochem 167, 175-180, 1987.
Author Unknown, Internet, Drug-coated stents help eliminate angioplasty problems, Mar. 18, 2002, www.cnn.com/2002/health/03/18/heart.angioplasty.ap/index.html, 3 pgs.
Ayers, G.M., et al., Amiodarone Instilled Into the Canine Pericardial Sac Migrates Transmurally to Produce Electrophysiologic Effects and Suppress Atrial Fibrillation; Journal of Cardiovascular Electrophysiology; vol. 7, No. 8; Aug. 1996; 713-721.
Lamanna, C., Thoughts on Action of Botulinum Toxin Suggested by Reversibility of Heart Effects; Botulinum and Tetanus Neurotoxins (edited by Dasgupta, B.R.); 1993 Plenum Press; 333-335.
McDermott, D.A., et al.; Use of and Indwelling Catheter for Examining Cardiovascular Responses to Pericardial Administration of Bradykinin in Rat; Cardiovascular Research; 1995; vol. 30; 39-46.
Galardi et al.: “The Local Injection of Botulinum Toxin Can Effect the Neural Control of Heart Rate Variability.” , Neurology, vol. 44, 1994, pp. A307-A308.
Kimura et al., “Negative Chronotropic Effect of Botulinum Toxin on Neonatal Rat Cardiac Mycocytes.” Biochem. Biophys. Res. Comm., vol. 244, 1998, pp. 275-279.
Dickson, E., Studies on the Manner in which the Toxin of Clostridium Botulinum Acts Upon the Body, J. Exper Med 37: 711-31 (1923) d.
Nattel, S., Comparative Mechanisms of Action of Antiarrhythmic Drugs, Am.J. Cardiol, 72: 13 F-17F (1993).
Wit, A., Electrophysiological Basis for Antiarrhythmic Drug Action, Clin. Physiol. Biochem. 3: 127-134 (1985).
Waxman, S., Persistent Primary Coronary Dilation Induced by Transatrial Delivery of Nitroglycerin into the Pericardial Space: A Novel Approach for Local Cardiac Drug Delivery, J Am Coll Cardiol 33: (7); 2073-2077 (1999).
Glaradi, G., The Local Injection of Botulinum Toxin Affect the Neural Control of Heart Rate Variability, Neurology 44; (Sup. 2): A307-A308 (1994).
Laham, R., Therapeutic Myocardial Angiogenesis Using Percutaneous Intrapericardial Drug Delivery, Clin & Cardiol; 22 (supp l): 16-19 (1999).
Laham, R., Subxyphoid Access of the Normal pericardium: A Novel Drug Delivery Technique, Cath & Cardiovasc Inter 47: 109-111 (1999).
Sonobe, T., Development of Intracoronary Local Adhesive delivery Technique, Int. J Artic Organs 20(6); 310-326 (1997).
Avitall, B., Iontophoretic Transmyocardial Drug Delivery. A Novel Approach to Antiarrhytmic Drug Therapy, Circulation 85: 1582-93 (1992).
Labhasetwar V., Epicardial Administration of Ibutilide from Polyurethane Matrices: Effects on Defibrillation Threshold and Electrophysiologic Parameters J. Cardiovasc Pharmacol 24: 826-40 (1994).
Lambert, C., Local Drug Delivery, Cath & Cardiovasc Diagn 41: 231 (1997).
Glazier, J., Site-Specific Intracoronary Thombolysis With Urokinase-Coated Hydrogel Balloons: Acute and Follow-Up Studies in 95 P
Brooks Gregory F.
Donovan Stephen
Allergan Inc.
Donovan Stephen
Nassif Claude L.
Tongue Lakia J.
Voet Martin A.
LandOfFree
Methods for treating restenosis with a botulinum neurotoxin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating restenosis with a botulinum neurotoxin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating restenosis with a botulinum neurotoxin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3774495